Tag: #Tirzepatide

Cleveland Clinic Study Evaluates Weight Changes after Discontinuation of Semaglutide or Tirzepatide

Among patients who started the treatment for obesity, the average weight change from baseline to discontinuation was -7.1% with semaglutide and -12.2 with tirzepatide.

WeightControl.com Interview with:
Hamlet Gasoyan, DS, PhD, MPH 
Staff, Internal Medicine 
Investigator, Center for Value-Based Care Research 
Assistant Professor of Medicine,
Cleveland Clinic Lerner College of Medicine of Case Western Reserve
Cleveland, OH

WeightControl.com:  What is the background for this study? 

Response: Despite the popularity of semaglutide and tirzepatide for obesity, discontinuation rates of these medications at 1-year range from 47% to 65%. Limited data are available about what additional weight management efforts patients pursue in real-world settings after discontinuing semaglutide or tirzepatide, and whether long-term weight changes after discontinuation follow the patterns reported in randomized clinical trials.

Continue reading “Cleveland Clinic Study Evaluates Weight Changes after Discontinuation of Semaglutide or Tirzepatide”